Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Intelligent Bio Solutions (INBS) announces a new partnership with Avon Freight Group, implementing its fingerprint drug testing solution across three UK sites. This marks Avon's first in-house drug testing program, replacing their previous external oral swab testing method. INBS has expanded its presence to over 400 accounts across 19 countries.
The partnership highlights INBS's growth in the UK drug testing market, which is projected to reach $453 million by 2030. The company's non-invasive, rapid testing solution offers a more efficient and respectful alternative to traditional methods. Following its FDA 510(k) submission in December 2024, INBS is preparing for U.S. market expansion in 2025, positioning itself as a scalable, cost-effective leader in the drug testing industry.
Intelligent Bio Solutions (INBS) annuncia una nuova partnership con Avon Freight Group, implementando la sua soluzione di testing per droghe basata su impronta digitale in tre sedi nel Regno Unito. Questo segna il primo programma di test per droghe interno di Avon, sostituendo il precedente metodo di test con tampone orale esterno. INBS ha ampliato la sua presenza a oltre 400 clienti in 19 paesi.
La partnership evidenzia la crescita di INBS nel mercato dei test per droghe nel Regno Unito, che si prevede raggiungerà 453 milioni di dollari entro il 2030. La soluzione di testing non invasiva e rapida dell'azienda offre un'alternativa più efficiente e rispettosa rispetto ai metodi tradizionali. Dopo la sua submission FDA 510(k) nel dicembre 2024, INBS si sta preparando per l'espansione nel mercato statunitense nel 2025, posizionandosi come un leader scalabile e conveniente nell'industria dei test per droghe.
Intelligent Bio Solutions (INBS) anuncia una nueva asociación con Avon Freight Group, implementando su solución de pruebas de drogas basada en huellas dactilares en tres ubicaciones del Reino Unido. Esto marca el primer programa interno de pruebas de drogas de Avon, reemplazando su anterior método de prueba con hisopo bucal externo. INBS ha expandido su presencia a más de 400 cuentas en 19 países.
La asociación destaca el crecimiento de INBS en el mercado de pruebas de drogas del Reino Unido, que se proyecta que alcanzará 453 millones de dólares para 2030. La solución de pruebas no invasivas y rápidas de la compañía ofrece una alternativa más eficiente y respetuosa que los métodos tradicionales. Tras su presentación 510(k) a la FDA en diciembre de 2024, INBS se está preparando para la expansión en el mercado estadounidense en 2025, posicionándose como un líder escalable y rentable en la industria de pruebas de drogas.
Intelligent Bio Solutions (INBS)는 Avon Freight Group과 새로운 파트너십을 발표하며, 영국의 세 곳에서 지문 기반 약물 검사 솔루션을 구현합니다. 이는 Avon의 첫 번째 내부 약물 검사 프로그램으로, 이전의 외부 구강 면봉 검사 방법을 대체합니다. INBS는 19개국에서 400개 이상의 고객으로 그 존재를 확대했습니다.
이번 파트너십은 INBS의 영국 약물 검사 시장에서의 성장을 강조하며, 시장은 2030년까지 4억 5천 3백만 달러에 이를 것으로 예상됩니다. 이 회사의 비침습적이고 신속한 검사 솔루션은 전통적인 방법에 비해 더 효율적이고 존중하는 대안을 제공합니다. INBS는 2024년 12월에 FDA 510(k) 제출 후, 2025년 미국 시장 확장을 준비하고 있으며, 약물 검사 산업에서 확장 가능하고 비용 효과적인 리더로 자리 잡고 있습니다.
Intelligent Bio Solutions (INBS) annonce un nouveau partenariat avec Avon Freight Group, mettant en œuvre sa solution de test de drogue par empreinte digitale sur trois sites au Royaume-Uni. Cela marque le premier programme interne de test de drogue d'Avon, remplaçant leur méthode précédente de test par écouvillon buccal externe. INBS a élargi sa présence à plus de 400 comptes dans 19 pays.
Ce partenariat met en lumière la croissance d'INBS sur le marché des tests de drogue au Royaume-Uni, qui devrait atteindre 453 millions de dollars d'ici 2030. La solution de test rapide et non invasive de l'entreprise offre une alternative plus efficace et respectueuse aux méthodes traditionnelles. Suite à sa soumission FDA 510(k) en décembre 2024, INBS se prépare pour une expansion sur le marché américain en 2025, se positionnant comme un leader évolutif et rentable dans l'industrie des tests de drogue.
Intelligent Bio Solutions (INBS) kündigt eine neue Partnerschaft mit Avon Freight Group an und implementiert seine Fingerabdruck-Drogentestlösung an drei Standorten im Vereinigten Königreich. Dies markiert das erste interne Drogen-Testprogramm von Avon, das die vorherige externe Methode mit Mundabstrichen ersetzt. INBS hat seine Präsenz auf über 400 Konten in 19 Ländern ausgeweitet.
Die Partnerschaft hebt das Wachstum von INBS im britischen Drogentestmarkt hervor, der voraussichtlich bis 2030 453 Millionen Dollar erreichen wird. Die nicht-invasive, schnelle Testlösung des Unternehmens bietet eine effizientere und respektvollere Alternative zu herkömmlichen Methoden. Nach der Einreichung bei der FDA 510(k) im Dezember 2024 bereitet sich INBS auf die Marktexpansion in den USA im Jahr 2025 vor und positioniert sich als skalierbarer, kosteneffizienter Marktführer in der Drogentestbranche.
- Expanded client network to over 400 accounts in 19 countries
- New partnership with Avon Freight Group for three UK sites
- Strong market opportunity with UK drug testing market projected to reach $453M by 2030
- Planned expansion into U.S. market following FDA 510(k) submission
- None.
Insights
The partnership with Avon Freight Group represents a strategic milestone for INBS, validating their technology in the important logistics and transport sector. Their fingerprint-based drug testing solution addresses key pain points in workplace screening: cost, invasiveness and operational disruption. With 400+ accounts across 19 countries, INBS demonstrates strong product-market fit and scalability.
The projected
Key growth catalysts include:
- Pending FDA 510(k) submission, potentially unlocking the massive U.S. market
- Rising workplace safety regulations and drug testing requirements
- Increasing adoption in safety-sensitive industries
- Cost pressures driving demand for efficient testing solutions
However, investors should consider execution risks:
- FDA approval timeline uncertainties
- Competition from established testing providers
- Resource requirements for U.S. market entry
- Need for sustained customer acquisition to achieve profitability
Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency
INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission
UK drug testing market projected to hit
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Avon Freight Group ("Avon") has selected its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing across its three UK sites, supporting proactive risk management and employee well-being. The addition of Avon further expands INBS’ client network of over 400 accounts in 19 countries.
Avon is implementing in-house drug testing for the first time, seeking a more respectful and practical alternative to the costly and intrusive random oral swab testing previously carried out by external providers. Avon's adoption of INBS' less invasive, rapid, and hygienic fingerprint sweat-based drug testing supports its efforts to improve workplace safety while maintaining a positive work culture.
Martin Bullimore, Commercial & Procurement Contracts Manager at Avon Freight Group, commented, "We've never had an in-house testing solution before, and moving to fingerprint drug testing is a big step forward for us. We recognized the need for a more proactive approach to workplace testing and appreciated the non-invasive nature of this solution. The system allows us to conduct random testing without disrupting operations or imposing on our employees' personal lives and reinforces our commitment to a safe, effective, and respectful workplace. The feedback has been extremely positive overall, with many stakeholders realizing its value.”
As more businesses in the logistics and transport sector recognize the limitations of traditional drug screening methods, solutions such as INBS' Drug Screening System are increasingly becoming the preferred choice. Market research estimates the UK Drug of Abuse Testing Services Market to be the fastest-growing regional market in Europe1, projected to reach
The Company expects further growth this year, following its U.S. FDA 510(k) submission in December 2024. Expansion into the U.S. presents significant opportunities for INBS and its innovative drug testing technology. The Company's unique, non-invasive solution addresses the challenges faced by safety-sensitive industries, streamlines drug testing processes, and provides an alternative that supports employee well-being and compliance. By leveraging its expertise and proven success in the UK, INBS aims to establish a strong foothold in the U.S. market.
About Avon Freight Group
Founded in the 1970s, Avon Freight Group has built a reputation for excellent customer-focused service by adapting to the evolving needs of its clients. Avon delivers reliable and cost-effective freight, distribution, and warehousing solutions across the UK, Ireland, Europe, and beyond through continued growth and investment in its warehouse, modern vehicle fleet, and technology. The company's dedicated, experienced team takes pride in exceeding expectations and working collaboratively with clients to achieve their goals.
For more information, visit: https://www.avonfreightgroup.co.uk
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
_________________________
Hyperlinks and website references in this release are provided for convenience only and do not incorporate the referenced content into this release.
1 Horizon Grand View Research. Europe Drug of Abuse Testing Services Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-of-abuse-testing-services-market/europe
2 Horizon Grand View Research. UK Drug of Abuse Testing Services Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-of-abuse-testing-services-market/uk
FAQ
What is the projected size of the UK drug testing market by 2030 for INBS?
How many accounts does INBS currently serve globally?
When is INBS planning to expand into the U.S. market?
What are the advantages of INBS's fingerprint drug testing solution?
Which UK company recently adopted INBS's drug testing solution?
